Claims:

Claim 1. Use of an antibody which is capable of binding to Interleukin 11 (IL-11) or IL-11 receptor α (IL-11Rα) and inhibiting IL-11 mediated signalling, in the manufacture of a medicament for use in a method of treating or preventing a disease or condition characterised by fibrosis of the liver.

Claim 2. The use according to claim 1, wherein the disease or condition characterised by fibrosis of the liver is in a human subject.

Claim 3. The use according to claim 1 or claim 2, wherein the disease or condition is associated with chronic liver disease.

Claim 4. The use according to claim 1 or claim 2, wherein the disease or condition is associated with liver cirrhosis.

Claim 5. The use according to any one of claims 1 to 4, wherein the disease or condition is non-alcoholic steatohepatitis (NASH).

Claim 6. The use according to any one of claims 1 to 4, wherein the disease or condition is chronic liver disease.

Claim 7. The use according to any one of claims 1 to 4, wherein the disease or condition is primary biliary cirrhosis (PBC).

Claim 8. The use according to any one of claims 1 to 4, wherein the disease or condition is schistosomal liver disease.

Claim 9. The use according to any one of claims 1 to 4, wherein the disease or condition is liver cirrhosis.

Claim 10. The use according to any one of claims 1 to 9, wherein the antibody is an IL-11 binding antibody.

Claim 11. The use according to any one of claims 1 to 9, wherein the antibody is an IL-11Rα binding antibody.

Claim 12. The use according to any one of claims 1 to 11, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

Claim 13. The use according to any one of claims 1 to 12, wherein the antibody is to be administered to a subject in which IL-11 or IL-11R expression is upregulated.

Claim 14. The use according to any one of claims 1 to 13, wherein the antibody is to be administered to a subject in which IL-11 or IL-11R expression has been determined to be upregulated.